In human airways, epithelial cells lining the lumen and intraluminal cells (e.g., polymorphonuclear cells) participate in the innate immune response. These cells secrete or express on their surfaces arginine-specific ADP ribosyltransferases. Defensins, antimicrobial proteins secreted by immune cells, are arginine-rich, leading us to hypothesize that ADP ribosylation could modify their biological activities. We found that an arginine-specific ADP ribosyltransferase-1 present on airway epithelial cells modifies Arg-14 of ␣ defensin-1. ADP-ribosylated defensin-1 had decreased antimicrobial and cytotoxic activities but still stimulated T cell chemotaxis and IL-8 release from A549 cells. Further, ADP-ribosylated defensin-1 inhibited cytotoxic and antimicrobial activities of unmodified defensin-1. We identified ADP-ribosylated defensin-1 in bronchoalveolar lavage fluid from smokers but not from nonsmokers, confirming its existence in vivo. Thus, airway mono-ADP-ribosyltransferases could have an important regulatory role in the innate immune response through modification of ␣ defensin-1 and perhaps other basic molecules, with alteration of their biological properties.
I
n the human airway, epithelial cells, in concert with intraluminal cells (e.g., macrophages), contribute to the innate immune response. Activation of airway epithelial cells releases proinflammatory mediators and chemotaxins, leading to the recruitment of inflammatory cells (e.g., neutrophils) (1, 2). Activated neutrophils, in turn, release azurophilic granules that contain human neutrophil peptides (HNP), small cationic peptides ranging in size from 29-33 aa (3). HNPs are characterized by a high arginine content and contain three pairs of disulfidelinked cysteines (4) . They have a broad spectrum of antimicrobial and cytotoxic activities and play an important role in the innate immune response against both Gram-positive and -negative bacteria, fungi, and certain enveloped viruses (5) (6) (7) (8) . High HNP levels have been found in airway secretions of patients with inflammatory lung diseases (9) (10) (11) .
A family of eukaryotic and prokaryotic mono-ADP ribosyltransferases (ARTs) catalyze the transfer of ADP ribose from NAD ϩ to arginine residues in proteins (12) . Among the monoARTs are bacterial products (e.g., cholera toxin), which are responsible for the clinical syndrome in disease (13) . A family of mammalian ARTs that are secreted or localized on the cell surface through glycosylphosphatidylinositol anchors (14) (15) (16) (17) (18) (19) are expressed preferentially on epithelial and inflammatory cells such as lymphocytes and neutrophils (17, 20) . Substrates of the five known mammalian ARTs (ART-1-5) include proteins that are involved in critical cellular events (e.g., lymphocyte activation, neutrophil chemotaxis) (21) (22) (23) . Two of these transferases, ART-1 and -5, specifically modify arginine residues in proteins. The finding of ARTs on airway epithelial and inflammatory cells prompted us to evaluate potential substrates for ADP ribosylation in the airway (24) . Because of the high arginine content of defensins and the substrate specificity of ARTs, we investigated whether HNP, specifically HNP-1, could be a substrate for ART-1, whether ADP-ribosylation of HNP altered its activities, and whether ADP-ribosylated HNP-1 exists in vivo. Our findings indicate a potentially important function for ADP ribosylation in regulating the activity of basic proteins such as HNP and demonstrate that ADP-ribosylated defensin has unique biological properties.
Methods
Cloning, Expression, and Purification of ART-1. We cloned wild-type ART-1 from a rabbit muscle cDNA library by PCR by using forward (5Ј-ACGTACA AGCT TAGCCACCTG GTGA-CACGTCGAGAC) and reverse (5Ј-ACGTACGGTACCGTC-CAGGTGGC AGGGCCTAGACTT) primers. PCR products were digested with HindIII and KpnI (Roche Molecular Biochemicals), and then subcloned into a pFLAG-MAC (Sigma) expression vector that was used to transform Escherichia coli ampicillin-resistant BL-21 (DE 3) competent cells (Novagen). Single colonies were grown in LB medium with ampicillin (50 g͞ml) to an optical density at 600 nm of 0.4 before adding isopropyl-D thiogalactoside (final concentration, 0.5 mM). After incubation for 2 h at 30°C, bacteria were pelleted by centrifugation (15 min, 3,200 ϫ g, 4°C), resuspended in 50 mM Tris (pH 8.0)͞5 mM EDTA͞lysozyme (0.25 mg/ml)͞1.5 M NaCl͞0.1 M MgCl 2 ͞DNase I (0.02 g/ml)͞protease inhibitor mixture (Boehringer Mannheim) (50 g/ml), sonified, and centrifuged (12,500 ϫ g, 45 min, 4°C). Supernatants were applied to anti-FLAG M2 affinity gel (Sigma) and eluted following the manufacturer's instructions. Eluates were concentrated at 4°C, using Centricon 10 columns (Millipore), with centrifugation at 4,300 ϫ g.
ART Assay. The ART activity of ART-1 was assayed as described (17) . For HNP modification by ART-1, we incubated synthetic HNP-1 (58 pmol, 2 g) (Bachem) in 200 l of 50 mM potassium phosphate, pH 7.5, with ART-1 (4.5 mmol) and 3 mM NAD ϩ . After overnight incubation at 30°C, the mixture was solubilized in 6 M guanidine and applied to a Vydac (Hesperia, CA) C18 column (The Nest Group, Southborough, MA) equilibrated with solution A (HPLC grade water, 0.1% trifluoroacetic acid). ADP-ribose-HNP-1 was separated from the unmodified form by gradient elution with solution B (100% isopropanol, 0.2% trifluoroacetic acid) at a flow rate of 1 ml͞min: 100% solution A, 0-20 min, linear gradient 0-60% of solution B 20-80 min, and 95% solution B 60-85 min. Fractions were analyzed by matrix-assisted laser desorption ionization (MALDI)-MS, as described (25) .
Electrospray MS Analysis of ADP-Ribosylated HNP-1. Samples (58 pmol, 2 g) of ADP-ribosyl-HNP-1 or HNP-1 were reduced by incubation in 50 l of 100 mM Tris⅐HCl (pH 8)͞1 mM EDTA͞20 mM DTT for 1 h at 37°C before incubation for 6 h at 37°C with Abbreviations: HNP, human neutrophil peptides; ARTs, ADP ribosyltransferases; MALDI, matrix-assisted laser desorption ionization; BAL, bronchoalveolar lavage.
trypsin (1 g) (Sigma) plus 100 mM NH 4 HCO 3 (total volume, 100 l). The modified site was identified by electrospray MS, as described (25) .
Antimicrobial and Chromium Release Assays. Antibacterial activity of HNP-1 and ADP-ribosyl-HNP-1 on E. coli ATCC43827 (American Type Culture Collection, Rockville, MD) was evaluated by a radial diffusion assay (26) .
Chromium-labeled A549 cells (American Type Culture Collection) were incubated (18 h, 37°C) in 100 l of serum-free RPMI medium (GIBCO) containing HNP-1 or ADP-ribosyl-HNP-1 (1.5 to 24 M) for quantification of defensin cytotoxicity assessed by chromium release from the cells (11) .
Effects of ADP-Ribosyl-HNP-1 on HNP-1 Antimicrobial and Cytotoxic
Activity. HNP-1 (100 nM) was incubated (1 h, 37°C) with ADP-ribosyl-HNP-1 (0-800 nM), before assay of antimicrobial activity on E. coli.
HNP-1 (12 M) was incubated with ADP-ribosyl-HNP-1 (1.5-12 M) for 1 h at 37°C before assay of chromium release. As control, we used HNP-1 and ADP-ribosyl-HNP-1 (1.5-12 M). Chemotaxis Assay. CD3 ϩ T cells were isolated from human peripheral blood prepared by leukopheresis (National Institutes of Health, Department of Transfusion Medicine, Bethesda, MD), as described (27) , and suspended in migration medium (RPMI 1640͞0.5% BSA͞25 mM Hepes). Inserts coated with collagen IV (Becton Dickinson) were placed in 24-well culture plates, forming upper and lower chambers, which were equilibrated with migration medium for 1 h at 37°C in an atmosphere of 5% CO 2 . After aspiration of wetting medium, migration medium (300 l) containing 5 ϫ 10 5 cells and migration medium (500 l) containing ADP-ribosyl-HNP-1 or HNP-1 (0.025-25 nM) were added to the upper and lower chambers, respectively. Plates were incubated at 37°C in 5% CO 2 for 4 h. Lymphocytes that migrated to the lower chamber were suspended in medium, collected by centrifugation and counted in a hemacytometer.
Isolation of ADP-Ribosyl-HNP-1 from Bronchoalveolar Lavage (BAL).
Samples (10 ml) of BAL fluids from 18 cigarette smokers (National Heart, Lung, and Blood Institute Institutional Review Board protocol no. 95-H-167) (total cells: 127 Ϯ 15 million) and 10 healthy nonsmokers (total cells: 33 Ϯ 5.8 million) (Table 1) were applied to SepPack C-18 cartridges (Waters) equilibrated in 10% isopropanol͞0.1% trifluoroacetic acid (TFA), washed with the same buffer, and eluted with 50% isopropanol͞0.1% TFA (1.5 ml). The eluted proteins were concentrated to 600 l in a vacuum centrifuge (Savant), adjusted to 6 M guanidine͞ 0.1% acetic acid and separated on a Vydac column C18 HPLC column. Absorbance (210 nm) peaks corresponding to the retention times of HNP-1 and ADP-ribosyl-HNP-1 were analyzed by MALDI-MS. Molecules with masses corresponding to ADP-ribosyl-HNP-1 were further characterized. We incubated ADP-ribosyl-HNP-1 (6 pmol͞0.2 g) in 200 l of 250 mM NaHCO 3 ͞25 mM MgCl 2 , alkaline phosphatase (5 g), and pyrophosphatase (5 g) (Sigma) for 30 min at 37°C before termination of the reaction with 6 M guanidine, separation of reaction products by RP-HPLC, and analysis by MALDI-MS. We also incubated ADP-ribosyl-HNP-1 (11 pmol, 0.42 g) overnight at 37°C with recombinant human ADP-ribosylarginine hydrolase (1 g) in 100 l of 50 mM Tris (pH 7.5)͞5 mM DTT͞10 mM Mg Cl 2 (28), followed by desalting and concentration using Zip-Tip C18 (Millipore), and analysis by MALDI-MS.
Results

Modification of HNP-1 by an Arginine-Specific Mono-ADP-Ribosyltransferase (ART-1).
After incubation of HNP-1 with NAD ϩ and͞or ART-1, the reaction products were separated by RP-HPLC, and analyzed by MALDI-MS (Fig. 1) . We identified peptides of mass 3,441 Da (retention time 48.5 min), consistent with HNP-1 (calculated 3,442 Da) and of 3,983 Da (retention time 46.5 min), consistent with mono-ADP-ribosyl-HNP (calculated 3,983 Da). As expected, modified HNP exhibited an absorbance peak at 258 nm not seen with HNP (Fig. 1d Inset) . The ADP ribose was released by incubation with ADPribosylarginine hydrolase, generating the unmodified defensin (data not shown).
To identify the modified amino acid in HNP-1, reduced ADP-ribosyl-HNP-1 was digested with trypsin, and the fragments were analyzed by MS. A peak of mass of 1,626.3 Da compatible with ADP-ribosylated fragment P 6 -15 (calculated 1,626.3 Da) was observed. This peak, unique to ADP-ribosylated HNP-1, was generated by inhibition of trypsin cleavage as a result of ADP ribosylation of Arg-14. Spectral analysis was consistent with the presence of adenosine.
Effects of Mono-ADP-Ribosylation of HNP-1 on Antimicrobial and
Cytotoxic Activities, Stimulation of T Cell Chemotaxis, and IL-8 Release from A549 Cells. We compared the antimicrobial and cytotoxic activities of HNP-1 and ADP-ribosylated HNP-1, synthesized as defined in Methods, by radial diffusion and chromium-release assays, respectively. ADP-ribosyl-HNP-1 was inactive on E. coli ATCC 43827 cells in the radial diffusion assay (Fig. 2a) and in the cytotoxicity assay using A549 cells (Fig. 2b) . ADP-ribosyl-HNP-1 blocked antimicrobial and cytotoxic activities of HNP-1 in a concentration-dependent manner (Fig. 3 a and b,  respectively) .
We measured IL-8 released into the medium after incubation of A549 cells with ADP-ribosyl-HNP-1 or HNP-1 for 12 ( Fig. 4a ) or 24 h (Fig. 4b) . At concentrations of 0.75 and 1.5 M, IL-8 release was significantly higher with ADP-ribosyl-HNP-1 than with the unmodified peptide. Using 1.5 M of peptide, we confirmed significantly larger amounts of IL-8 in medium after incubation with ADP-ribosyl-HNP-1 (P ϭ 0.01) (data not shown). At a peptide concentration of 3 M, no differences were observed. We also investigated the chemotactic activity of ADP-ribosyl-HNP-1 toward CD3 ϩ lymphocytes. ADP-ribosyl-HNP-1 retained its ability to recruit T cells, at a level similar to that noted with unmodified HNP-1 (Fig. 4c) .
Identification of ADP-Ribosyl-HNP-1 in BAL Fluid. To identify ADPribosyl-HNP-1 in humans, we performed BAL on 18 smokers and 10 nonsmokers, none of whom had signs of pulmonary infection. Characteristics of the smokers and lavage findings are summarized in Table 1 . The two populations did not differ significantly in age, gender, or pulmonary function (data not shown). The total number of cells recovered from BAL of smokers was 4-fold that of controls (P Ͻ 0.001), with a significantly greater absolute number of neutrophils (data not shown). RP-HPLC analysis of BAL fluid from 18 smokers revealed peaks with the same elution time as authentic HNP in 12; 4 of these 12 samples showed peaks with elution times identical to that of ADP-ribosyl-HNP-1 (Fig. 5a) . MALDI-MS analysis demonstrated a molecule with a mass of 3,983 Da, confirming the presence of ADP-ribosyl-HNP-1(calculated 3,983 Da) (Fig. 5b1) . Defensins were not detected in BAL fluids from the nonsmoker group.
We further characterized the putative ADP-ribosyl-HNP-1 by incubating it with pyrophosphatase and alkaline phosphatase to remove the ADP moiety, producing ribosyl-HNP, or with ADPribosylarginine hydrolase, which cleaves the ribose-arginine linkage, releasing HNP. After incubation with pyrophosphatase and alkaline phosphatase, MALDI-MS analysis of the peak separated by RP-HPLC showed a molecule of 3,575 Da, consistent with ribosyl-HNP-1, produced by removal of ADP from the ADP-ribosyl-HNP-1 (Fig. 5b2) (calculated 3,574 Da). The site of linkage of ADP-ribose to HNP was confirmed after (Fig. 5b3) .
Discussion
Glycosylphosphatidylinositol-anchored ARTs (ART-1, 3, 4) are located on the apical surface of airway epithelial cells, as well as on lymphocytes and neutrophils, consistent with the possibility that ARTs could have a regulatory role in airway inflammation. Because these transferases use arginine as an ADP-ribose acceptor, defensins, arginine-rich cationic peptides are potential substrates. In this study, we demonstrated that, in vitro, synthetic HNP-1 is a substrate for ART-1. ADP ribosylation of HNP-1 significantly reduced both its antimicrobial and cytotoxic activities but enhanced its ability to release IL-8 from A549 cells. Further, ADP-ribosyl HNP-1 retained its activity as a chemoattractant for T lymphocytes. Importantly, ADP-ribosyl-HNP-1 inhibited the antimicrobial and cytotoxic activities of HNP-1. Thus, ADP-ribosylation of Arg-14 in HNP-1 yielded a molecule with unique biological properties, which could modulate defensin activity as well as T cell chemotaxis and neutrophil recruitment via IL-8 release from epithelial cells. Because transferases require NAD ϩ for ADP ribosylation, a supply of extracellular NAD ϩ is necessary at the cell surface. NAD ϩ may be released into the airway lumen during inflammation, cell lysis, and͞or apoptosis, and could be transiently and locally available for ADP ribosylation. We questioned whether there would be sufficient NAD ϩ in the extracellular space for the transferase-catalyzed modification and whether our in vitro studies were relevant to the human airway in vivo. Cigarette smoking results in pulmonary inflammation with increased numbers of neutrophils in the lung. We showed by HPLC, MALDI-MS, and enzymatic modification the presence of ADPribosyl-(arginine) HNP-1 in BAL fluids from habitual cigarette smokers. Consistent with the observation that HNP-1 is the most abundant antimicrobial factor in BAL fluids (29) , we found that the major modified ␣ defensin was HNP-1.
Defensins exhibit a wide range of antimicrobial activities but are also cytotoxic for several types of mammalian cells, including human epithelial and endothelial cells (30, 31) . During lung inflammation, neutrophil defensins reach concentrations that, in vitro, are cytotoxic for airway epithelial cells (9) (10) (11) 30) . Several mechanisms could modify their cytotoxic and antimicrobial activities. Defensins are synthesized as inactive propeptides (32) . In intestinal Paneth cells, the metalloprotease matrilysin cleaves the propeptide, releasing the anionic inhibitory segment and generating active defensin (33) . In the airway, binding of defensins to ␣1 antitrypsin and ␣1 antichymotrypsin inhibited their cytotoxicity for airway epithelial cells (11) . In cystic fibrosis, the high salt concentration of the epithelial lining fluid may block defensin antimicrobial action to the detriment of the host (34, 35) . Our study suggests that ADP ribosylation can also modify defensin activities. Because ADP-ribosyl-HNP-1 inhibited antimicrobial and cytotoxic activities of HNP-1, while retaining its T cell chemotactic properties and promoting neutrophil recruitment, it may have an important role as a regulator of the inflammatory response. Such properties could make ADP-ribosylated HNP-1 useful as a therapeutic agent in pulmonary inflammation and lung diseases.
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